AbbVie announces provincial reimbursement for Rinvoq (upadacitinib) for the treatment of rheumatoid arthritis and psoriatic arthritis in Alberta, New Brunswick, Ontario, Quebec and Saskatchewan

1 December 2022 - AbbVie today announced that Rinvoq is now listed as a special authorisation medication or exception medication status ...

Read more →

Medical industry advocates urge Ontario to offer cheaper versions of prescription medications

11 October 2022 - Medical industry advocates are urging the Ontario government to offer cheaper versions of certain prescription medications ...

Read more →

Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, join a growing list of provinces providing public drug plan reimbursement for Teva Canada’s Ajovy (fremanezumab), for the preventive treatment of migraine in adults

17 May 2022 - Teva Canada welcomes the recently announced public formulary coverage for Ajovy (fremanezumab) by Ontario, British Columbia, ...

Read more →

Boehringer Ingelheim Canada announces reimbursement for Ofev (nintedanib) in seven public drug plans for the treatment of progressive fibrosing interstitial lung diseases

3 May 2022 - Boehringer Ingelheim is pleased to announce that Ofev (nintedanib), is now available for public reimbursement in Quebec, ...

Read more →

Astellas announces reimbursement for Xospata (gilteritinib) in most provinces for patients with relapsed or refractory acute myeloid leukaemia with a FLT3 mutation

21 April 2022 - Having access to an additional treatment option offers hope for Canadian adult AML patients with relapsed ...

Read more →

ALS Canada marks Rare Disease Day 2022 by calling on Ontario to champion expedited access to ALS therapies

28 February 2022 - The ALS Society of Canada Cana today marks Rare Disease Day 2022 by calling on the ...

Read more →

Valeo Pharma obtains public reimbursement for Enerzair Breezhaler and Atectura Breezhaler in Ontario, Manitoba and New Brunswick

24 February 2022 - Private insurance coverage across Canada exceeds 90%. ...

Read more →

Baqsimi (nasal glucagon) rescue treatment for severe hypoglycaemia now covered in Ontario

28 January 2022 - Lilly Canada is pleased to announce that as of 31 January 2022, Baqsimi (glucagon nasal powder) ...

Read more →

Outdated criteria for drug plan reimbursement obstruct evidence based care

12 October 2021 - An important flaw in the funding approach used by Canada’s public drug plans is highlighted by the ...

Read more →

Ontario providing access to life changing treatment for cystic fibrosis patients

24 September 2021 - Ontario is now providing coverage for Trikafta, the latest and most effective treatment option for cystic fibrosis ...

Read more →

Cystic fibrosis patients, advocates urge Ontario government to provide ‘miracle drug’ funding

20 August 2021 - An Ontario teen living with Cystic Fibrosis and her mother are hoping to shine a light ...

Read more →

Dupixent (dupilumab) now publicly reimbursed in Ontario and New Brunswick for the treatment of moderate to severe atopic dermatitis

25 May 2021 - Dupixent is the only biologic medicine approved by Health Canada to treat moderate to severe atopic dermatitis. ...

Read more →

Valeo Pharma’s Redesca and Redesca HP to be covered under the Ontario Public Drug Benefit Program

28 April 2021 - Additional provincial coverage expected to follow. ...

Read more →

Cystic fibrosis patients call on Premier Ford to provide immediate access to life saving treatments

18 March 2021 - Ontarians with cystic fibrosis made an emotional plea to Premier Ford this week in a video that ...

Read more →

Ontario makes commitment to funding CF drugs after approval process completed

19 February 2021 - Ontario’s Health Minister Christine Elliott says life-saving cystic fibrosis medications that are inching their way through ...

Read more →